Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 8/20 | 0.47 |
| ▸ | CDK1 | P06493 | 8/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843640 | 0.93 | CCNB2 (0.47) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843545 | 0.93 | CDK1 (0.54) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843611 | 0.92 | CDK1 (0.45) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843495 | 0.92 | CDK2 (0.49) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843550 | 0.91 | CDK2 (0.46) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843662 | 0.88 | ADORA3 (0.41) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL19370287 | 0.88 | CCNB2 (0.47) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843534 | 0.86 | CDK2 (0.48) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL22843632 | 0.83 | NT5E (0.54) | CDK1CCNB1CDK2NT5EMAPT | |
| SCHEMBL22843642 | 0.81 | CDK1 (0.56) | CDK1CDK2NT5EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | CCNB2 4107/4885CDK1 4327/4885CCNB1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.